Veracyte, Inc. (VCYT) - Q1 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2026. Veracyte, Inc. is a global diagnostics company providing genomic tests for cancer diagnosis, prognosis, and treatment decisions. Key products include Decipher Prostate, Afirma (thyroid), Prosigna (breast), and Decipher Bladder. The company operates primarily through Laboratory Developed Tests (LDTs) in the U.S. and In Vitro Diagnostics (IVD) internationally. As of May 1, 2026, there were approximately 79.8 million shares of common stock outstanding.
Key Financial Metrics
| Metric (in thousands) | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenue | $139,071 | $114,473 |
| Gross Profit | $101,159 | $79,508 |
| Gross Margin | 72.7% | 69.5% |
| Net Income | $28,707 | $7,047 |
| Diluted EPS | $0.35 | $0.09 |
| Operating Cash Flow | $35,215 | $5,362 |
| Cash & Short-Term Investments | $439,060 | $240,631 (Beginning Q1 2025) |
| Total Debt | $0 | $0 |
Note: The company has no long-term debt. Total liabilities are primarily operating lease obligations and accrued liabilities.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 21% year-over-year (YoY), driven by a 26% increase in testing revenue ($135.1M vs. $107.3M). This growth was fueled by a 19% increase in diagnostic test volume and improved average selling prices (ASP).
- Biopharmaceutical Decline: Biopharmaceutical and other revenue dropped 92% to $0.3M due to the discontinuation of services in France following the restructuring of Veracyte SAS in August 2025.
- Profitability Surge: Net income increased 307% to $28.7M. Operating income jumped 680% to $22.6M, largely due to revenue growth and a significant reduction in General and Administrative (G&A) expenses.
- Expense Shifts:
- R&D: Increased 53% to $27.1M, primarily due to reclassifying software development costs from G&A and increased investment in the TrueMRD platform and Prosigna LDT.
- G&A: Decreased 30% to $23.7M, driven by the reclassification of software costs to R&D, lower professional fees, and reduced contingent consideration revaluations.
- Other Income: Increased 62% to $7.3M, boosted by a $4.2M settlement of escrow claims and higher interest income.
Guidance, Outlook, and Risks
- Strategic Initiatives: Management is focusing on the launch of the TrueMRD platform for minimal residual disease detection and transitioning Prosigna to an LDT model in the U.S. in 2026.
- Liquidity: The company maintains a strong liquidity position with $439.1M in cash and short-term investments. Operating cash flow improved significantly to $35.2M.
- Risks & Contingencies:
- Legal: Veracyte is engaged in patent infringement litigation against Sonic Healthcare USA regarding ThyroSeq v3. A jury trial is scheduled for Q1 2027.
- Reimbursement: Revenue growth depends on securing favorable coverage decisions and reimbursement rates from third-party payers, which face pressure to limit utilization.
- Supply Chain: Reliance on single-source suppliers for reagents and components poses a risk to operations.
- Geopolitical: Ongoing conflicts in the Middle East and Ukraine may disrupt operations, particularly in Israel (C2i acquisition).
Investor Verification Checklist
- Reimbursement Rates: Verify the sustainability of the improved Average Selling Price (ASP) and collection rates cited as drivers for revenue growth.
- R&D Capitalization: Confirm the classification of software development costs moved from G&A to R&D to ensure accurate future expense forecasting.
- Escrow Settlement: Note that the $4.2M escrow settlement in "Other Income" is a non-recurring item and should be excluded when assessing core operating profitability.
- Test Volume vs. Revenue: Monitor the correlation between the 19% volume increase and revenue growth to ensure it is not solely driven by price increases or prior-period collections.
- Legal Exposure: Track the progress of the patent litigation against Sonic Healthcare USA for potential financial impact.